Caris Life Sciences (NASDAQ:CAI) Reaches New 1-Year Low – Should You Sell?

Caris Life Sciences, Inc. (NASDAQ:CAI) hit a new 52-week low on Wednesday . The stock traded as low as $21.09 and last traded at $21.13, with a volume of 404299 shares traded. The stock had previously closed at $22.17.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Canaccord Genuity Group upped their target price on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Wall Street Zen upgraded Caris Life Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Evercore set a $38.00 price target on Caris Life Sciences in a research note on Monday, January 5th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $34.00.

Caris Life Sciences Stock Performance

The company has a market capitalization of $6.07 billion and a price-to-earnings ratio of -46.74. The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79. The company’s 50 day moving average is $26.28.

Insider Transactions at Caris Life Sciences

In other news, insider Luke Thomas Power sold 62,250 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the transaction, the insider owned 99,571 shares in the company, valued at approximately $2,646,597.18. The trade was a 38.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Hedge Funds Weigh In On Caris Life Sciences

Several institutional investors have recently bought and sold shares of CAI. BNP Paribas Financial Markets grew its position in shares of Caris Life Sciences by 57,052.2% in the 4th quarter. BNP Paribas Financial Markets now owns 685,826 shares of the company’s stock valued at $18,504,000 after purchasing an additional 684,626 shares during the period. AXQ Capital LP bought a new stake in shares of Caris Life Sciences during the fourth quarter worth $329,000. ProShare Advisors LLC acquired a new stake in shares of Caris Life Sciences during the fourth quarter worth $336,000. Seven Grand Managers LLC lifted its position in Caris Life Sciences by 395.1% in the 4th quarter. Seven Grand Managers LLC now owns 495,095 shares of the company’s stock valued at $13,358,000 after acquiring an additional 395,095 shares in the last quarter. Finally, UBS Group AG increased its holdings in Caris Life Sciences by 825.9% during the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock worth $58,924,000 after purchasing an additional 1,948,107 shares in the last quarter.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.